Innoviva Unternehmenskultur

Mr. Michael W. Aguiar, also known as Mike, has been the Chief Executive Officer and President of Innoviva, Inc. (formerly Theravance Inc.) since August 15, 2014. Mr. Aguiar served as the Chief Financial Officer of Theravance Inc since March 7, 2005 and served as its Principal Accounting Officer and Treasurer. He served as Senior Vice President of Finance at Innoviva, Inc. since March 7, 2005 and served as Secretary. He served as Vice President of Finance at Gilead Sciences. In his two years as Gilead's Vice President of Finance, he managed approximately 100 finance professionals in nine countries. In this capacity, he was responsible for Gilead's Controllership, Treasury, Financial Planning & Analysis, Tax, SEC reporting, Risk Management and Business Unit Finance. Mr. Aguiar has significant business transaction experience, most recently on Gilead's acquisition of Triangle Pharmaceuticals, has led financings and oversaw significant portions of Gilead's Sarbanes-Oxley Section 404 implementation efforts. He held a similar position at Immunex Corporation in Seattle. He spent six years with Honeywell International in a variety of financial positions of increasing responsibility, including, most recently, Chief Financial Officer and Vice President of Finance at Honeywell Electronic Materials. He has been a Director of Innoviva, Inc. since August 5, 2014. Mr. Aguiar Holds a BS in biology from UC Irvine and an MBA in finance from the University of Michigan.

Mr. Eric d'Esparbes has been the Chief Financial Officer and Senior Vice President of Innoviva, Inc. since October 2014 and is responsible for overseeing financial and IT operations. Mr. d'Esparbes has more than 20 years of finance strategy and structuring, accounting and management experience in the energy sector. He served as Senior Vice President of Joule Unlimited, Inc. He served as Chief Financial Officer of AEI Asia Ltd. at AEI Services LLC. Mr. d'Esparbes served as Chief Financial Officer of Joule Unlimited, Inc. since December 2, 2010, where he was responsible for overseeing all of the company's financial, tax, treasury and accounting activities. He served as Vice President of Finance for AEI Services, which owns and operates more than 50 energy infrastructure companies in 20 countries. He was responsible for optimizing the capital structure of AEI's global portfolio of energy assets and also helped to launch and grow its Asia division. Mr. d'Esparbes served senior finance positions for Meiya Power Company Limited (a former subsidiary of PSEG Global, an Asia-based power company with 18 investment companies and Hydro-Quebec International, the international unit of one of the world's largest hydro power companies.

Mr. Michael Eric Faerm has been Chief Business Officer and Senior Vice President at Innoviva, Inc. since July 13, 2015. Mr. Faerm has 17 years of pharmaceutical and biotechnology experience, spanning equity research, biopharmaceutical industry and investment banking roles. He served as a Director and Senior Pharmaceuticals Equity Research Analyst at Wells Fargo Securities, LLC, Research Division and was employed till June 2015. He was an Equity Analyst at Wachovia Securities, LLC, Research Division. Previously, Mr. Faerm served as a Research Analyst at Cr???dit Suisse AG, Research Division until December 14, 2012. He spent seven years in equity research at Cr???dit Suisse AG and was its Senior Specialty Pharmaceuticals and Generics Analyst. He was previously a member of the United States major pharmaceuticals team at the firm. Prior to that, Mr. Faerm spent four years working in the pharmaceutical industry for Forest Laboratories and Regeneron Pharmaceuticals, where he held positions in business development and strategic financial planning. Before moving into the pharmaceutical industry, he spent four years in investment banking as a member of Merrill Lynch's global healthcare team. While at Credit Suisse, Mr. Faerm was recognized by Institutional Investor magazine as the top ???Rising Star of Wall Street Research??? in the specialty pharmaceuticals sector. He earned a Master's degree in Business Administration from Harvard Business School. Mr. Faerm also holds a Master of Science in Civil Engineering from Stanford University and a Bachelor of Science in Civil Engineering from Columbia University.

Mr. Jeffrey A. Hagenah, Ph.D serves as Chief Patent Counsel and Vice President of Theravance Inc. Mr. Hagenah holds JD in Law from University of California, Berkeley - School of Law from 1993-1996, Ph.D. in Chemistry from University of California, Los Angeles from 1979-1984 and BS Degree in Chemistry from California State University-Long Beach from 1974-1979.

Dr. Theodore J. Witek, Jr., also known as Ted, MBA, PhD, serves as Chief Scientific Officer and Senior Vice President of Innoviva, Inc. (formerly known as Theravance Inc.). Dr. Witek served as a Senior Vice President of Corporate Partnerships, Clinical and Medical Affairs at Innoviva, Inc. since July 2, 2014. Dr. Witek served as Chief Executive Officer and President of Boehringer Ingelheim (Canada) Ltd./Lt???e. He served as President and Chief Executive Officer of Boehringer Ingelheim (Canada) Ltd. since 2008 and Head of the Prescription Medicine Business. Dr. Witek served as Managing Director of Boehringer Ingelheim Portugal. He had been with Boehringer Ingelheim since 1983 and including served as its Director of Respiratory and Immunology Clinical Research. Dr. Witek is a Member of CEO Advisory Board of Lumira Capital Corp. He has been the Chairman of EHAVE, Inc. since January 10, 2017 and its Director since November 18, 2016. He has been an Independent Director of Helix Biopharma Corp. since September 24, 2016. Dr. Witek served as Director of Canada's Research-Based Pharmaceutical Companies (Rx&D). He was appointed to the Ontario Health Innovation Council and is an Associate Professor at the University of Toronto's Leslie Dan Faculty of Pharmacy. He was appointed to the Ontario Heath Innovation Council. Dr. Witek is the author of more than 100 scientific papers as well as several chapters and books. He is a Senior Fellow at the Institute of Health Policy, Management and Evaluation of The University of Toronto and Professor at the Dalla Lana School of Public Health and Faculty of Pharmacy. Dr. Witek holds an M.B.A. from Henley Management College in the UK, a Doctor of Public Health from Columbia University and a Master of Public Health from Yale University.